Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.8%. By the end of trading, Amgen rose 88 cents (1.1%) to $82.91 on light volume. Throughout the day, 3.2 million shares of Amgen exchanged hands as compared to its average daily volume of 4.3 million shares. The stock ranged in a price between $81.98-$83.07 after having opened the day at $82.07 as compared to the previous trading day's close of $82.03. Other companies within the Drugs industry that increased today were:
), up 19.7%,
), up 16.8%,
), up 11.5%, and
), up 10.1%.
- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $63.43 billion and is part of the
sector. The company has a P/E ratio of 17.6, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 27.8% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.
TheStreet Ratings rates Amgen as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
- You can view the full Amgen Ratings Report.
On the negative front,
), down 78.5%,
), down 36.7%,
), down 17.6%, and
), down 11.1%, were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.
FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!
Free download now